Samsung Epis Holdings announced on the 9th that its subsidiary Samsung Bioepis has signed a 'Joint Technology Development and License-in Option Agreement for Modified Antibodies' with Protiina, a protein analysis platform company.

■ Key Terms of the Agreement The core of this agreement is to jointly carry out a national project based on Protiina's SPID (Single-molecule Protein Interaction Detection) platform and to secure a license-in option for novel antibody candidate materials derived from it. Samsung Bioepis will hold option rights to the substance patents of antibody candidate materials discovered in the future, and upon exercising the option to pursue product development, it will also secure rights to the corresponding product.

The development target consists of novel antibody candidate materials discovered through High-Throughput Screening technology utilizing Protiina's SPID platform.

■ National Project-Based Collaboration This agreement was concluded based on a national project titled 'Development and Validation of Antibody Biopharmaceuticals Using AI Models,' which Samsung Bioepis, Protiina, and Seoul National University have been jointly conducting since October 2025.

• ■ Contract Schedule and Financial Terms
• Contract date: July 9, 2026
• Contract period: October 1, 2025 – December 31, 2027

The agreement includes an upfront payment, development and sales milestones, and royalty terms based on revenue. The overall contract value and detailed terms were not disclosed by mutual agreement between the two companies. However, the company stated that the contract value exceeds the smaller of 2.5% of its consolidated equity or revenue for 2025.

■ Risk Factors This is a conditional agreement, and expense recognition may vary depending on the progress of clinical trials and product approval. The contract may be terminated if regulatory authorities decide to halt research and development or if product approval fails.

Additionally, payments made under the agreement may be refunded under certain conditions, and there is a possibility of early termination due to a material breach by either party, mutual agreement, or changes in collaborative, financial, legal, or technical circumstances.